Monopar Therapeutics (MNPR) EBITDA (2017 - 2025)

Monopar Therapeutics has disclosed EBITDA across 9 years of filings, most recently posting -$3.5 million for Q3 2025.

• EBITDA for Q3 2025 came in at -$3.5 million, down 164.71% year-over-year; the trailing twelve-month figure through Sep 2025 was -$9.8 million (down 48.22% YoY), and the FY2024 annual result was -$15.6 million, down 419.13% from the prior year.
• EBITDA came in at -$3.5 million for Q3 2025 at Monopar Therapeutics, down from -$2.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$57.0 in Q2 2021 to a low of -$3.5 million in Q3 2025.
• The 5-year median for EBITDA is -$2.4 million (2025), against an average of -$2.0 million.
• Across the five-year window, EBITDA jumped 100.0% in 2021 and sank 4809936.84% in 2022, its largest moves.
• Monopar Therapeutics' EBITDA stood at -$2.7 million in 2021, then decreased by 9.4% to -$2.9 million in 2022, then soared by 33.22% to -$2.0 million in 2023, then jumped by 32.37% to -$1.3 million in 2024, then tumbled by 164.71% to -$3.5 million in 2025.
• The last three EBITDA figures came in at -$3.5 million (Q3 2025), -$2.4 million (Q2 2025), and -$2.6 million (Q1 2025), per Business Quant data.